HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nutrition & Obesity Medicine
Meta-analysis
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
May 4, 2026
Psychiatry
Meta-analysis
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
May 1, 2026
Nutrition & Obesity Medicine
RCT
Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity
Semaglutide Cuts Insulin Needs By Half In Type 1 Diabetes
A post hoc analysis of an RCT found that semaglutide 1 mg/week significantly reduced total daily insulin dose by 22.6% over 26 weeks in adul…
Semaglutide reduces insulin needs quickly in type 1 diabetes patients, offering a new hope for better blood sugar control and weight managem…
Diab Care
May 1, 2026
Psychiatry
RCT
Semaglutide improves physical quality of life in schizophrenia with prediabetes
Semaglutide improves physical quality of life in adults with schizophrenia and obesity
This secondary analysis of a randomized trial in 154 adults with schizophrenia, prediabetes, and overweight or obesity found that once-weekl…
A secondary analysis of a trial found that once-weekly semaglutide improved physical quality of life in adults with schizophrenia and obesit…
May 1, 2026
Drug Pipeline
RCT
Tirzepatide improves standard and intensive therapeutic target attainment versus semaglutide in adults with type 2 diabetes
New drug helps more patients hit four key health goals at once
This post hoc analysis of a randomised phase 3 study included 1879 adults with type 2 diabetes followed for 40 weeks.
A new diabetes medicine helps more people hit their blood sugar, weight, and blood pressure goals at the same time
May 1, 2026
Diabetes & Endocrinology
Meta-analysis
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
May 1, 2026
Diabetes & Endocrinology
Meta-analysis
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
May 1, 2026
Cardiology
Cohort
Baseline vitamin D levels linked to semaglutide glycemic and weight outcomes in type 2 diabetes
Higher Vitamin D levels help Semaglutide work better for diabetes
This observational cohort study of 5,384 adults with type 2 diabetes found that higher baseline vitamin D levels were associated with greate…
New data shows higher Vitamin D levels help Semaglutide lower blood sugar and weight more effectively in diabetes patients.
Frontiers
Apr 28, 2026
Diabetes & Endocrinology
Phase III
Semaglutide high dose for weight reduction in people with Type 2 Diabetes
New drug helps obese diabetics lose weight and control sugar
This randomized controlled trial in 512 people with excess weight and Type 2 Diabetes compared high-dose semaglutide to placebo and lower do…
New research shows a specific injection helps people with obesity and diabetes lose weight and control their blood sugar levels better than …
CT.gov
Apr 27, 2026
Drug Pipeline
Sys. Review
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Frontiers
Apr 27, 2026
Diabetes & Endocrinology
Meta-analysis
Network Meta-Analysis Finds Tirzepatide and Semaglutide Most Effective for Weight Loss in Adults
New Weight Loss Drugs Protect Your Heart and Lower Death Risk
A systematic review and network meta-analysis of 63,909 adults found that all obesity medications produced greater weight loss than placebo.
New data from 66 trials shows top obesity drugs significantly reduce heart events and death while helping with liver and joint pain issues f…
medRxiv
Apr 24, 2026
Diabetes & Endocrinology
Cohort
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
medRxiv
Apr 24, 2026